2023
Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment
de Oliveira M, de Barros P, de Mathis M, Boavista R, Chacon P, Echevarria M, Ferrão Y, de Queiroz Vattimo E, Lopes A, Torres A, Diniz J, Fontenelle L, do Rosário M, Shavitt R, Miguel E, da Silva R, da Conceição Costa D. Brazilian Research Consortium on Obsessive-Compulsive Spectrum Disorders guidelines for the treatment of adult obsessive-compulsive disorder. Part I: pharmacological treatment. Brazilian Journal Of Psychiatry 2023, 45: 146-161. PMID: 36749887, PMCID: PMC10154009, DOI: 10.47626/1516-4446-2022-2891.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntipsychotic AgentsAripiprazoleBrazilClomipramineHumansObsessive-Compulsive DisorderRisperidoneSelective Serotonin Reuptake InhibitorsTreatment OutcomeConceptsSelective serotonin reuptake inhibitorsAdult obsessive-compulsive disorderObsessive-compulsive disorderPharmacological treatmentReuptake inhibitorsEvidence-based pharmacological interventionsFirst-line pharmacological treatmentAmerican Psychiatric Association guidelinesEvidence-based pharmacological treatmentFirst-line treatmentNorepinephrine reuptake inhibitorsPrimary outcome measureSerotonin reuptake inhibitorsGlutamate-modulating agentsHigh-quality evidenceAmerican Heart AssociationLevel of evidenceTreatment of OCDBrazilian Research ConsortiumAdult patientsHeart AssociationTolerable dosesAssociation guidelinesTreatment recommendationsPharmacological interventions
2022
Associations of medication with subcortical morphology across the lifespan in OCD: Results from the international ENIGMA Consortium
Ivanov I, Boedhoe PSW, Abe Y, Alonso P, Ameis SH, Arnold PD, Balachander S, Baker JT, Banaj N, Bargalló N, Batistuzzo MC, Benedetti F, Beucke JC, Bollettini I, Brem S, Brennan BP, Buitelaar J, Calvo R, Cheng Y, Cho KIK, Dallaspezia S, Denys D, Diniz JB, Ely BA, Feusner JD, Ferreira S, Fitzgerald KD, Fontaine M, Gruner P, Hanna GL, Hirano Y, Hoexter MQ, Huyser C, Ikari K, James A, Jaspers-Fayer F, Jiang H, Kathmann N, Kaufmann C, Kim M, Koch K, Kwon JS, Lázaro L, Liu Y, Lochner C, Marsh R, Martínez-Zalacaín I, Mataix-Cols D, Menchón JM, Minuzzi L, Morer A, Morgado P, Nakagawa A, Nakamae T, Nakao T, Narayanaswamy JC, Nurmi EL, Oh S, Perriello C, Piacentini JC, Picó-Pérez M, Piras F, Piras F, Reddy YCJ, Manrique DR, Sakai Y, Shimizu E, Simpson HB, Soreni N, Soriano-Mas C, Spalletta G, Stern ER, Stevens MC, Stewart SE, Szeszko PR, Tolin DF, van Rooij D, Veltman DJ, van der Werf YD, van Wingen GA, Venkatasubramanian G, Walitza S, Wang Z, Watanabe A, Wolters LH, Xu X, Yun JY, Zarei M, Zhang F, Zhao Q, Jahanshad N, Thomopoulos SI, Thompson PM, Stein DJ, van den Heuvel OA, O'Neill J, Group T, Poletti S, Fridgeirsson E, Ikuta T, de Wit S, Vriend C, Kasprzak S, Kuno M, Takahashi J, Miguel E, Shavitt R, Hough M, Pariente J, Ortiz A, Bertolín S, Real E, Segalàs C, Moreira P, Sousa N, Narumoto J, Yamada K, Tang J, Fouche J, Kim T, Choi S, Ha M, Park S. Associations of medication with subcortical morphology across the lifespan in OCD: Results from the international ENIGMA Consortium. Journal Of Affective Disorders 2022, 318: 204-216. PMID: 36041582, DOI: 10.1016/j.jad.2022.08.084.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntipsychotic AgentsBenzodiazepinesChildChild, PreschoolCross-Sectional StudiesHumansLongevityMagnetic Resonance ImagingObsessive-Compulsive DisorderSelective Serotonin Reuptake InhibitorsConceptsObsessive-compulsive disorderUnmedicated patientsOlder adultsAssociation of medicationVolumes of putamenSubcortical brain structuresReuptake inhibitorsVentricular hypertrophyHippocampal atrophyMedicated patientsPsychotropic medicationsTherapeutic responseHippocampal volumeStriatal volumeSubcortical nucleiPatientsPsychotic disordersAntipsychoticsSubcortical morphologyStructural MRINormal agingBrain structuresBenzodiazepinesOCD patientsENIGMA consortiumWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part I: Anxiety disorders
Bandelow B, Allgulander C, Baldwin D, da Conceição Costa D, Denys D, Dilbaz N, Domschke K, Eriksson E, Fineberg N, Hättenschwiler J, Hollander E, Kaiya H, Karavaeva T, Kasper S, Katzman M, Kim Y, Inoue T, Lim L, Masdrakis V, Menchón J, Miguel E, Möller H, Nardi A, Pallanti S, Perna G, Rujescu D, Starcevic V, Stein D, Tsai S, Van Ameringen M, Vasileva A, Wang Z, Zohar J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part I: Anxiety disorders. The World Journal Of Biological Psychiatry 2022, 24: 79-117. PMID: 35900161, DOI: 10.1080/15622975.2022.2086295.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnxietyAnxiety DisordersBiological PsychiatryChildHumansObsessive-Compulsive DisorderSelective Serotonin Reuptake InhibitorsStress Disorders, Post-TraumaticConceptsSocial anxiety disorderCognitive behavioral therapyAnxiety disordersPanic disorder/agoraphobiaMixed anxiety disordersPosttraumatic stress disorderSerotonin-norepinephrine reuptake inhibitorsSelective serotonin reuptake inhibitorsTreatment of anxietyFirst-line psychotherapySelective mutismBehavioral therapySeparation anxietyStress disorderSpecific phobiaObsessive-CompulsiveReuptake inhibitorsAnxietyNon-pharmacological interventionsBiological Psychiatry (WFSBP) GuidelinesFirst-line medicationSerotonin reuptake inhibitorsAdolescentsAssessment of medicationsPsychotherapyWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part II: OCD and PTSD
Bandelow B, Allgulander C, Baldwin D, da Conceição Costa D, Denys D, Dilbaz N, Domschke K, Hollander E, Kasper S, Möller H, Eriksson E, Fineberg N, Hättenschwiler J, Kaiya H, Karavaeva T, Katzman M, Kim Y, Inoue T, Lim L, Masdrakis V, Menchón J, Miguel E, Nardi A, Pallanti S, Perna G, Rujescu D, Starcevic V, Stein D, Tsai S, Van Ameringen M, Vasileva A, Wang Z, Zohar J. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders – Version 3. Part II: OCD and PTSD. The World Journal Of Biological Psychiatry 2022, 24: 118-134. PMID: 35900217, DOI: 10.1080/15622975.2022.2086296.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnxietyAnxiety DisordersBiological PsychiatryChildHumansObsessive-Compulsive DisorderSelective Serotonin Reuptake InhibitorsStress Disorders, Post-TraumaticTreatment OutcomeConceptsSelective serotonin reuptake inhibitorsRepetitive transcranial magnetic stimulationCognitive behavioral therapyFirst-line treatmentDeep brain stimulationSSRI treatmentBiological Psychiatry (WFSBP) GuidelinesSecond-line medicationsNon-pharmacological treatmentSerotonin reuptake inhibitorsNon-pharmacological interventionsTreatment-resistant casesTranscranial magnetic stimulationWorld FederationTreatment of anxietyPosttraumatic stress disorderTreatment of OCDReuptake inhibitorsMedication treatmentPharmacological treatmentSNRI venlafaxineInternet-CBTConsensus panelMagnetic stimulationBrain stimulationKetamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review
Bandeira ID, Lins-Silva DH, Cavenaghi VB, Dorea-Bandeira I, Faria-Guimarães D, Barouh JL, Jesus-Nunes AP, Beanes G, Souza LS, Leal GC, Sanacora G, Miguel EC, Sampaio AS, Quarantini LC. Ketamine in the Treatment of Obsessive-Compulsive Disorder: A Systematic Review. Harvard Review Of Psychiatry 2022, 30: 135-145. PMID: 35267254, DOI: 10.1097/hrp.0000000000000330.Peer-Reviewed Original ResearchMeSH KeywordsHumansKetamineObsessive-Compulsive DisorderRetrospective StudiesSelective Serotonin Reuptake InhibitorsTreatment OutcomeConceptsObsessive-compulsive disorderSystematic reviewN-methyl-D-aspartate receptor antagonistAppropriate washout periodOpen-label trialPlacebo-controlled trialFirst-line treatmentRetrospective chart reviewUse of ketamineEffects of ketamineMeta-analysis protocolCombination of ketaminePubMed/MEDLINEPreferred Reporting ItemsMore effective treatmentsPotent N-methyl-d-aspartate receptor antagonistKetamine treatmentChart reviewGlutamate modulatorsGood tolerabilityReuptake inhibitorsWashout periodCase reportGlutamatergic neurotransmissionReceptor antagonist
2019
Treatments used for obsessive–compulsive disorder—An international perspective
Brakoulias V, Starcevic V, Albert U, Arumugham S, Bailey B, Belloch A, Borda T, Dell'Osso L, Elias J, Falkenstein M, Ferrao Y, Fontenelle L, Jelinek L, Kalogeraki L, Kay B, Laurito L, Lochner C, Maina G, Marazziti D, Martin A, Matsunaga H, Miguel E, Morgado P, Mourikis I, Pasquini M, Rivera R, Potluri S, Reddy J, Riemann B, do Rosario M, Shavitt R, Stein D, Viswasam K, Wang Z, Fineberg N. Treatments used for obsessive–compulsive disorder—An international perspective. Human Psychopharmacology Clinical And Experimental 2019, 34: e2686. PMID: 30628745, DOI: 10.1002/hup.2686.Peer-Reviewed Original ResearchAdultAntipsychotic AgentsBenzodiazepinesDeep Brain StimulationFemaleHumansInternationalityMaleMiddle AgedObsessive-Compulsive DisorderPsychosurgerySelective Serotonin Reuptake Inhibitors
2018
Adaptive treatment strategies for children and adolescents with Obsessive-Compulsive Disorder: A sequential multiple assignment randomized trial
Fatori D, de Bragança Pereira CA, Asbahr FR, Requena G, Alvarenga PG, de Mathis MA, Rohde LA, Leckman JF, March JS, Polanczyk GV, Miguel EC, Shavitt RG. Adaptive treatment strategies for children and adolescents with Obsessive-Compulsive Disorder: A sequential multiple assignment randomized trial. Journal Of Anxiety Disorders 2018, 58: 42-50. PMID: 30025255, DOI: 10.1016/j.janxdis.2018.07.002.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentChildCognitive Behavioral TherapyFemaleFluoxetineHumansMaleObsessive-Compulsive DisorderPsychotherapy, GroupSelective Serotonin Reuptake InhibitorsTreatment OutcomeConceptsGroup cognitive behavioral therapySequential multiple assignmentTreatment failureInitial treatmentBaseline Yale-Brown ObsessiveChildhood OCDEffective initial treatmentProvision of treatmentCompulsive Scale scoresCognitive behavioral therapyAdaptive treatment strategiesYale-Brown ObsessiveSame regimenObsessive-compulsive disorderTreatment strategiesSymptom reductionPrimary analysisScale scoreFluoxetineTime pointsWeeksTreatmentChildrenEffect sizeTrials
2017
Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
Costa DLC, Diniz JB, Requena G, Joaquim MA, Pittenger C, Bloch MH, Miguel EC, Shavitt RG. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder. The Journal Of Clinical Psychiatry 2017, 78: e766-e773. PMID: 28617566, DOI: 10.4088/jcp.16m11101.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcysteineAdolescentAdultAgedAnxiety DisordersComorbidityDepressive DisorderDouble-Blind MethodDrug ResistanceDrug Therapy, CombinationFemaleHumansMaleMiddle AgedObsessive-Compulsive DisorderPsychiatric Status Rating ScalesPsychometricsSelective Serotonin Reuptake InhibitorsYoung AdultConceptsTreatment-resistant obsessive-compulsive disorderObsessive-compulsive disorderY-BOCS scoresN-acetylcysteineNAC groupYale-Brown Obsessive Compulsive Scale scoresTreatment-resistant OCD patientsBaseline Y-BOCS scoresTreatment-Resistant ObsessivePrimary outcome measureAnxiety symptomsDSM-IV criteriaSymptom dimensionsCompulsive Scale scoresSpecific OCD symptom dimensionsOCD symptom dimensionsAntioxidant medicationsAbdominal painPlacebo groupGlutamate modulatorsSecondary outcomesTertiary hospitalOutpatient clinicSeverity scoreWeek 16
2016
International prescribing practices in obsessive–compulsive disorder (OCD)
Brakoulias V, Starcevic V, Belloch A, Dell'Osso L, Ferrão Y, Fontenelle L, Lochner C, Marazziti D, Martin A, Matsunaga H, Miguel E, Reddy Y, do Rosário M, Shavitt R, Sundar A, Stein D, Viswasam K. International prescribing practices in obsessive–compulsive disorder (OCD). Human Psychopharmacology Clinical And Experimental 2016, 31: 319-324. PMID: 27271200, DOI: 10.1002/hup.2541.Peer-Reviewed Original ResearchPrevalence and correlates of electroconvulsive therapy delivery in 1001 obsessive-compulsive disorder outpatients
dos Santos-Ribeiro S, Lins-Martins N, Frydman I, do Rosário M, Ferrão Y, Shavitt R, Yücel M, Miguel E, Fontenelle L. Prevalence and correlates of electroconvulsive therapy delivery in 1001 obsessive-compulsive disorder outpatients. Psychiatry Research 2016, 239: 145-148. PMID: 27137976, DOI: 10.1016/j.psychres.2016.03.020.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntipsychotic AgentsElectroconvulsive TherapyFemaleHumansMaleMiddle AgedObsessive-Compulsive DisorderOutpatientsPsychotic DisordersSelective Serotonin Reuptake InhibitorsSeverity of Illness IndexYoung AdultConceptsElectroconvulsive therapyObsessive-compulsive disorderOCD patientsHigher global severitySerotonin reuptake inhibitorsObsessive-compulsive disorder outpatientsContamination/washing symptomsRates of psychosisDifferent specialized centersAdequate trialReuptake inhibitorsSpecialized centersGlobal severityGreater suicidalityDisorder outpatientsTherapy deliveryTerms of responseAssessment BatteryPatientsOCD symptomsSymptomsWashing symptomsAntipsychoticsOutpatientsTherapyUse of benzodiazepines in obsessive–compulsive disorder
Starcevic V, Berle D, do Rosário M, Brakoulias V, Ferrão Y, Viswasam K, Shavitt R, Miguel E, Fontenelle L. Use of benzodiazepines in obsessive–compulsive disorder. International Clinical Psychopharmacology 2016, 31: 27-33. PMID: 26426443, DOI: 10.1097/yic.0000000000000100.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Anxiety AgentsAnxietyBenzodiazepinesCross-Sectional StudiesDiagnostic and Statistical Manual of Mental DisordersDrug Therapy, CombinationFemaleHumansMaleMiddle AgedObsessive-Compulsive DisorderPsychiatric Status Rating ScalesSelective Serotonin Reuptake InhibitorsSocioeconomic FactorsConceptsObsessive-compulsive disorderBDZ useOCD patientsUse of benzodiazepinesTreatment of OCDBrazilian Research ConsortiumAdditional medicationTreatment guidelinesMulticentre studyReuptake inhibitorsObsessive-compulsive spectrum disordersBenzodiazepine useMarked anxietyPatientsMedicationsBDZDisordersResearch ConsortiumCurrent age
2014
Musical obsessions: A comprehensive review of neglected clinical phenomena
Taylor S, McKay D, Miguel E, De Mathis M, Andrade C, Ahuja N, Sookman D, Kwon J, Huh M, Riemann B, Cottraux J, O’Connor K, Hale L, Abramowitz J, Fontenelle L, Storch E. Musical obsessions: A comprehensive review of neglected clinical phenomena. Journal Of Anxiety Disorders 2014, 28: 580-589. PMID: 24997394, DOI: 10.1016/j.janxdis.2014.06.003.Peer-Reviewed Original ResearchAdolescentAdultAgedAged, 80 and overAntipsychotic AgentsAvoidance LearningChildCognitive Behavioral TherapyDiagnosis, DifferentialFearFemaleHallucinationsHumansImaginationMaleMiddle AgedModels, PsychologicalMusicObsessive BehaviorObsessive-Compulsive DisorderSelective Serotonin Reuptake InhibitorsYoung AdultAn updated review of antidepressants with marked serotonergic effects in obsessive–compulsive disorder
Pizarro M, Fontenelle L, Paravidino D, Yücel M, Miguel E, de Menezes G. An updated review of antidepressants with marked serotonergic effects in obsessive–compulsive disorder. Expert Opinion On Pharmacotherapy 2014, 15: 1391-1401. PMID: 24766145, DOI: 10.1517/14656566.2014.914493.Peer-Reviewed Original ResearchMeSH KeywordsAntidepressive AgentsHumansObsessive-Compulsive DisorderSelective Serotonin Reuptake InhibitorsConceptsDouble-blind studyObsessive-compulsive disorderPathophysiology of OCDEfficacy of desvenlafaxineEfficacy of antidepressantsShort-term treatmentOlder antidepressantsSerotonergic effectsClinical trialsSerotonergic systemNew agentsAntidepressantsSystematic reviewReliable efficacyEfficacyUpdated reviewClomipramineOCD symptomsDisordersTreatmentCurrent studyReviewSSRIsDuloxetineMirtazapine
2013
Can early improvement be an indicator of treatment response in obsessive-compulsive disorder? Implications for early-treatment decision-making
da Conceição Costa D, Shavitt R, Cesar R, Joaquim M, Borcato S, Valério C, Miguel E, Diniz J. Can early improvement be an indicator of treatment response in obsessive-compulsive disorder? Implications for early-treatment decision-making. Journal Of Psychiatric Research 2013, 47: 1700-1707. PMID: 23948637, DOI: 10.1016/j.jpsychires.2013.07.006.Peer-Reviewed Original ResearchConceptsBaseline Y-BOCS scoresSerotonin reuptake inhibitorsEarly improvementTreatment responseY-BOCS scoresBaseline Yale-Brown ObsessiveLogistic regressionAdequate pharmacological treatmentPotential predictive factorsWeeks of treatmentGreater reductionObsessive-compulsive disorder patientsStepwise logistic regressionWarrants further investigationYale-Brown ObsessiveClinical featuresReuptake inhibitorsObsessive-compulsive disorderPharmacological treatmentPredictive factorsMajor depressionDisorder patientsOCD treatment responseCompulsive ScaleWeeks
2012
CLINICAL PREDICTORS OF LONG‐TERM OUTCOME IN OBSESSIVE‐COMPULSIVE DISORDER
Jakubovski E, Diniz J, Valerio C, Fossaluza V, Belotto‐Silva C, Gorenstein C, Miguel E, Shavitt R. CLINICAL PREDICTORS OF LONG‐TERM OUTCOME IN OBSESSIVE‐COMPULSIVE DISORDER. Depression And Anxiety 2012, 30: 763-772. PMID: 23109056, DOI: 10.1002/da.22013.Peer-Reviewed Original ResearchConceptsLong-term outcomesObsessive-compulsive disorderPositive family historyGroup cognitive behavioral therapyDepressive disorderFamily historyOCD patientsOnset of OCDInitial treatment modalityComorbid psychiatric disordersPercent of subjectsBeck depression scoresDuration of OCDCognitive behavioral therapyYale-Brown ObsessiveUntreated patientsClinical factorsClinical predictorsInitial treatmentOpen trialWorse prognosisClinical variablesPharmacological treatmentPsychiatric comorbidityTreatment modalitiesDifferential prefrontal gray matter correlates of treatment response to fluoxetine or cognitive-behavioral therapy in obsessive–compulsive disorder
Hoexter M, Dougherty D, Shavitt R, D'Alcante C, Duran F, Lopes A, Diniz J, Batistuzzo M, Evans K, Bressan R, Busatto G, Miguel E. Differential prefrontal gray matter correlates of treatment response to fluoxetine or cognitive-behavioral therapy in obsessive–compulsive disorder. European Neuropsychopharmacology 2012, 23: 569-580. PMID: 22841131, DOI: 10.1016/j.euroneuro.2012.06.014.Peer-Reviewed Original ResearchConceptsGray matter volumeMedial prefrontal cortexCognitive behavioral therapyObsessive-compulsive disorderTreatment responseTreatment-naïve OCD patientsTreatment groupsMagnetic resonance imagingMatter volumeOrbitofrontal cortexLateral orbitofrontal cortexSymptom improvementOCD patientsFluoxetine treatment groupTrial of fluoxetineSerotonin reuptake inhibitorsAdequate therapeutic approachStructural magnetic resonance imagingCBT treatment groupRight medial prefrontal cortexGroup-based cognitive behavioral therapyRegional gray matter volumeStructural MRI scansDistinct brain regionsYale-Brown Obsessive
2011
A Double-Blind, Randomized, Controlled Trial of Fluoxetine Plus Quetiapine or Clomipramine Versus Fluoxetine Plus Placebo for Obsessive-Compulsive Disorder
Diniz J, Shavitt R, Fossaluza V, Koran L, de Bragança Pereira C, Miguel E. A Double-Blind, Randomized, Controlled Trial of Fluoxetine Plus Quetiapine or Clomipramine Versus Fluoxetine Plus Placebo for Obsessive-Compulsive Disorder. Journal Of Clinical Psychopharmacology 2011, 31: 763-768. PMID: 22020357, DOI: 10.1097/jcp.0b013e3182367aee.Peer-Reviewed Original ResearchConceptsY-BOCS scoresFluoxetine groupTreatment regimenSelective serotonin reuptake inhibitorsPlacebo-controlled trialSevere adverse eventsSerotonin reuptake inhibitorsMain outcome measuresObsessive-compulsive disorder patientsCompulsive Scale scoresYale-Brown ObsessiveFluoxetine monotherapyAdverse eventsReuptake inhibitorsObsessive-compulsive disorderPrimary diagnosisOutcome measuresDisorder patientsScale scoreFluoxetineMental disordersQuetiapinePatientsStatistical ManualClomipramineGray Matter Volumes in Obsessive-Compulsive Disorder Before and After Fluoxetine or Cognitive-Behavior Therapy: A Randomized Clinical Trial
Hoexter M, de Souza Duran F, D'Alcante C, Dougherty D, Shavitt R, Lopes A, Diniz J, Deckersbach T, Batistuzzo M, Bressan R, Miguel E, Busatto G. Gray Matter Volumes in Obsessive-Compulsive Disorder Before and After Fluoxetine or Cognitive-Behavior Therapy: A Randomized Clinical Trial. Neuropsychopharmacology 2011, 37: 734-745. PMID: 22030709, PMCID: PMC3260985, DOI: 10.1038/npp.2011.250.Peer-Reviewed Original ResearchMeSH KeywordsAdultBrainCognitive Behavioral TherapyFemaleFluoxetineHumansImage Processing, Computer-AssistedMagnetic Resonance ImagingMaleMiddle AgedObsessive-Compulsive DisorderOrgan SizeSelective Serotonin Reuptake InhibitorsTreatment OutcomeConceptsCognitive behavior therapyObsessive-compulsive disorderGray matter volumeLeft putamenClinical trialsOCD patientsGM volumeMatter volumeSignificant GM volume changesPathophysiology of OCDFluoxetine-treated patientsGM volume abnormalitiesMatched-healthy controlsTreatment-naive patientsFirst-line treatmentStructural brain abnormalitiesGM volume changesCBT-treated patientsGroup cognitive behavior therapySmaller GM volumeRegional brain volumesRegional brain morphologyAnterior cingulate cortexStructural magnetic resonanceRegional gray matter volumeGroup cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: A practical clinical trial
Belotto-Silva C, Diniz J, Malavazzi D, Valério C, Fossaluza V, Borcato S, Seixas A, Morelli D, Miguel E, Shavitt R. Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: A practical clinical trial. Journal Of Anxiety Disorders 2011, 26: 25-31. PMID: 21907540, DOI: 10.1016/j.janxdis.2011.08.008.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedCognitive Behavioral TherapyFemaleFluoxetineFollow-Up StudiesHumansMaleMiddle AgedObsessive-Compulsive DisorderPsychiatric Status Rating ScalesPsychotherapy, GroupSelective Serotonin Reuptake InhibitorsTreatment OutcomeConceptsGroup cognitive behavioral therapyY-BOCS scoresPsychiatric comorbidityCognitive behavioral therapySSRI groupMean Y-BOCS scoreSelective serotonin reuptake inhibitorsBaseline Y-BOCS scoresY-BOCS reductionSerotonin reuptake inhibitorsMore psychiatric comorbiditiesPractical clinical trialsReal-world populationObsessive-compulsive disorder outpatientsBroad inclusion criteriaAdditional psychiatric comorbidityReuptake inhibitorsObsessive-compulsive disorderClinical effectivenessClinical trialsMajor depressionCGI ratingsInclusion criteriaComorbiditiesWorse responseRisk factors for early treatment discontinuation in patients with obsessive-compulsive disorder
Diniz J, Malavazzi D, Fossaluza V, Belotto-Silva C, Borcato S, Pimentel I, Miguel E, Shavitt R. Risk factors for early treatment discontinuation in patients with obsessive-compulsive disorder. Clinics 2011, 66: 387-393. PMID: 21552660, PMCID: PMC3071996, DOI: 10.1590/s1807-59322011000300004.Peer-Reviewed Original ResearchMeSH KeywordsAdultCognitive Behavioral TherapyCombined Modality TherapyComorbidityEpidemiologic MethodsFemaleHumansMaleObsessive-Compulsive DisorderPatient ComplianceSelective Serotonin Reuptake InhibitorsSocioeconomic FactorsTime FactorsTreatment OutcomeConceptsEarly treatment discontinuationSelective serotonin reuptake inhibitorsTreatment discontinuationObsessive-compulsive disorder patientsObsessive-compulsive disorderDisorder patientsFirst-line treatmentGroup of patientsSerotonin reuptake inhibitorsStructured Clinical InterviewLogistic regression analysisLogistic regression modelsGeneralized anxiety disorderCognitive behavioral therapyMann-Whitney testClinical characteristicsCompliant patientsDiscontinuation ratesReuptake inhibitorsPsychiatric comorbidityClinical correlatesTreatment modalitiesRisk factorsSomatization disorderDiscontinuation